Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort
Real-world outcomes in mantle cell lymphoma patients show how newer therapies are translating into improved survival outside of controlled clinical trials.
Using the prospective REALYSA registry, this study characterized contemporary treatment and survival outcomes in MCL patients treated outside of clinical trials. The analysis highlights how evolving therapies translate into real-world practice in this aggressive B-cell lymphoma.
What the study was
- Study design
- Prospective cohort / Real-world registry (REALYSA)
- Population
- Adults with mantle cell lymphoma
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Hematological oncology
Why it surfaced
Large real-world prospective registry data on MCL outcomes; bridges clinical trial efficacy and real-world practice for a high-unmet-need lymphoma.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.